CRIS CURIS INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1108205 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-36.9%
TTM net income YoY49.8%
TTM EPS YoY90.5%
Revenue 3-yr CAGR-12.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-100.2%
Net margin-299.7%
FCF margin—
EBITDA margin-98.5%
Returns
ROE-693.9%
ROA-61.3%
ROIC (approx.)—
Asset turnover0.20x
Leverage & solvency
Liabilities / assets57.2%
Debt / equity0.00x
Current ratio1.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio22.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $9.44M | $10.91M | $10.02M | $10.16M | $10.65M |
| R&D expense | $28.25M | $38.56M | $39.50M | $43.28M | $34.88M |
| SG&A expense | $14.05M | $16.79M | $18.65M | $19.65M | $17.30M |
| Operating income | -$5.71M | -$44.54M | -$48.33M | -$53.02M | -$42.06M |
| Interest expense | — | — | — | — | $0 |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$7.58M | -$43.39M | -$47.41M | -$56.67M | -$45.44M |
| EBITDA | -$5.54M | -$44.34M | -$48.08M | -$52.79M | -$41.91M |
| EPS (basic) | -0.58 | -6.88 | -8.96 | -12.14 | 0.50 |
| EPS (diluted) | -0.58 | -6.88 | -8.96 | -12.14 | 0.50 |
| Weighted avg. shares (diluted) | 13.16M | 6.31M | 5.29M | 4.67M | 91.57M |
| Balance sheet | |||||
| Cash & equivalents | $5.06M | $20.54M | $27.23M | $20.29M | $40.74M |
| Short-term investments | — | $0 | $29.65M | $65.97M | $75.87M |
| Receivables | $0 | $3.35M | $2.79M | $2.98M | $3.22M |
| Current assets | $6.92M | $26.39M | $60.91M | $92.12M | $122.38M |
| PP&E, net | $62,000 | $231,000 | $434,000 | $689,000 | $505,000 |
| Goodwill | $8.98M | $8.98M | $8.98M | $8.98M | $8.98M |
| Total assets | $19.97M | $41.27M | $77.28M | $108.85M | $162.30M |
| Current liabilities | $14.08M | $19.03M | $22.02M | $10.01M | $13.44M |
| Short-term debt | $0 | $7.56M | $8.50M | — | $0 |
| Total liabilities | $14.50M | $47.26M | $57.61M | $62.30M | $71.59M |
| Shareholders' equity | $5.46M | -$6.00M | $19.67M | $46.55M | $90.71M |
| Shares outstanding | 646,537 | 8.49M | 5.89M | 4.83M | 91.65M |
| Cash flow statement | |||||
| Operating cash flow | -$27.20M | -$39.56M | -$38.43M | -$54.34M | -$37.62M |
| Capital expenditure | — | — | $0 | $416,000 | $0 |
| Free cash flow | — | — | -$38.43M | -$54.75M | -$37.62M |
| Investing cash flow | $2.50M | $29.44M | $37.79M | $33.02M | -$47.90M |
| Financing cash flow | $9.77M | $3.44M | $7.58M | $867,000 | -$4.17M |
| Depreciation & amortization | $169,000 | $203,000 | $255,000 | $233,000 | $158,000 |
| Stock-based compensation | $4.02M | $5.93M | $6.00M | $6.75M | $5.28M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.